Fermenta Biotech Ltd
P&L
Quarterly Consolidated
vs Q3 FY25
Fermenta Biotech's FY25 Revenues Surge by 39% to INR 481.3 Cr, Net Profit INR 76.4 Cr
28 May 2025 · 28 May 2025, 06:02 pm
Summary
Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, announced its financial results for the year ended 31 March 2025. The company reported a 39% YoY increase in consolidated revenue to INR 481.3 crore and a net profit of INR 76.4 crore, compared to a loss in the same period last year.
Key Highlights
- 1
FY25 Revenues INR 481.3 cr, up 39% YoY
- 2
Net Profit INR 76.4 cr vs year-ago loss
- 3
Consolidated EBITDA for FY25 INR 121.6 crore, up 209% YoY
- 4
Q4FY25 Consolidated Revenues INR 143.7 crore, up 40% YoY; down 9% QoQ
- 5
Human nutrition volume grew by 48% over FY24
- 6
Animal nutrition volume grew by 24% over FY24
- 7
German subsidiary showed 412% growth in FY25 revenue
- 8
US subsidiary showed 81% growth in FY25 revenue
Management Comments
Prashant Nagre
Managing Director
FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia, and breakthrough innovations like Vitadee Green—the world's first pharmacopeial-grade plant-based Vitamin D3—demonstrate our resilience and technical leadership.
Informational and educational content only. Not investment advice.